Tan et al. have reported that patients with HER2-low non-metastatic breast cancer had favorable relapse-free survival (RFS) and OS compared to patients with HER2-zero breast cancer in both hormone receptor-positive and negative groups, but the absolute differences were modest and not clinically significant enough to support de-escalation of treatment11. Here, ERBB2 is linked to breast cancer.